Global demand for biocompatible, bio‑degradable polymers is reshaping the medical device sector. Among the candidates, polyglycolic acid (PGA) stands out for its rapid hydrolytic breakdown into harmless water and carbon dioxide, a property that aligns with tightening environmental regulations and the push for sustainable healthcare solutions.

Medical Polyglycolic Acid (PGA) Market – View in Detailed Research Report

---

Market Snapshot

In 2023 the Global Medical Polyglycolic Acid market generated USD 1,154 million, and analysts project a rise to USD 1,949.66 million by 2032, a 6.00% CAGR over the decade. North America, accounting for USD 332.42 million in 2023, is expected to grow at 5.14% from 2025 to 2032, reflecting the region’s robust adoption of biodegradable sutures and drug delivery systems.

---

What Is Polyglycolic Acid?

PGA is a synthetic polymer that combines high tensile strength with a controlled, water‑driven degradation pathway. Unlike conventional plastics, PGA does not persist in the environment; after its functional life it converts to water and carbon dioxide, making it an attractive material for implants, sutures, and drug carriers that must disappear safely within the body or ecosystem.

---

Top 10 Companies in the PGA Market

10️⃣ 1. Sinopec

Headquarters: Beijing, China
Key Offering: High‑purity PGA for sutures and drug carriers

Sinopec has leveraged its petrochemical infrastructure to produce PGA grades that meet the stringent mechanical and sterility requirements of surgical applications. The company’s focus on high‑grade polymers positions it as a preferred supplier for implantable sutures and tissue scaffolds.

Sustainability & Growth Initiatives:

• 2024 partnership with Medtronic for biodegradable stents
• 2025 launch of PGA‑based drug‑release system
• 2026 expansion of production capacity in Shanghai

---

9️⃣ 2. Shanghai Pujing Chemical

Headquarters: Shanghai, China
Key Offering: Homopolymer PGA for surgical sutures

Shanghai Pujing Chemical specializes in fine‑grade PGA that delivers superior tensile strength and sterility, meeting the demands of high‑precision surgical procedures. The firm’s commitment to quality has earned it ISO 13485 certification.

Sustainability & Growth Initiatives:

• 2024 joint venture with Johnson & Johnson
• 2025 ISO 13485 certification
• 2026 R&D into copolymer blends for tailored degradation

---

8️⃣ 3. Yulin Energy Group

Headquarters: Yulin, China
Key Offering: Copolymer PGA for controlled‑release drug carriers

Yulin Energy Group has expanded into copolymer PGA, enabling customized degradation rates that accelerate drug release by up to 15%. The company’s focus on renewable feedstocks aligns with global sustainability targets.

Sustainability & Growth Initiatives:

• 2024 partnership with Pfizer
• 2025 launch of biodegradable drug implant
• 2026 expansion of R&D facilities

---

7️⃣ 4. Danhua Technology

Headquarters: Shenzhen, China
Key Offering: Block copolymer PGA for fracture fixation

Danhua Technology develops block copolymer PGA that enhances mechanical strength while maintaining resorbable properties, making it ideal for load‑bearing orthopedic implants.

Sustainability & Growth Initiatives:

• 2024 acquisition of a polymer extrusion plant
• 2025 environmental management system certification
• 2026 launch of biodegradable plates

---

6️⃣ 5. Huayang Medical

Headquarters: Guangzhou, China
Key Offering: PGA tissue‑engineering scaffolds

Huayang Medical produces PGA scaffolds with nano‑surface modification, supporting cellular adhesion and tissue regeneration. The firm collaborates with academic institutions to optimize water usage during production.

Sustainability & Growth Initiatives:

• 2024 collaboration with Tsinghua University
• 2025 launch of hydrogel‑coated scaffold
• 2026 expansion into Southeast Asia

---

5️⃣ 6. Shenzhen Polymtek Biomaterial

Headquarters: Shenzhen, China
Key Offering: PGA‑based stitched reinforcement for wound closure

Polymtek Biomaterial offers PGA‑reinforced sutures that incorporate antimicrobial agents, reducing infection risk in surgical sites.

Sustainability & Growth Initiatives:

• 2024 partnership with Bausch & Lomb
• 2025 launch of antimicrobial suture
• 2026 expansion of production line

---

4️⃣ 7. Kureha

Headquarters: Tokyo, Japan
Key Offering: Homopolymer PGA for surgical sutures

With a legacy in polymer chemistry, Kureha supplies high‑grade PGA sutures across Asia, focusing on biocompatibility and mechanical integrity.

Sustainability & Growth Initiatives:

• 2024 collaboration with Stryker
• 2025 launch of eco‑friendly suture line
• 2026 expansion of R&D facilities in Japan

---

3️⃣ 8. Evonik

Headquarters: Essen, Germany
Key Offering: Copolymer PGA for drug delivery systems

Evonik’s specialty chemicals division delivers copolymer PGA with tunable degradation, catering to pharmaceutical companies seeking controlled release.

Sustainability & Growth Initiatives:

• 2024 partnership with Novartis
• 2025 launch of biodegradable drug delivery system
• 2026 expansion of European production

---

2️⃣ 9. Teleflex

Headquarters: Morrisville, USA
Key Offering: PGA components for minimally invasive surgical tools

Teleflex supplies PGA parts that meet strict sterility and biocompatibility standards, integrating closed‑loop manufacturing to reduce waste.

Sustainability & Growth Initiatives:

• 2024 acquisition of a PGA plant
• 2025 ISO 9001 certification
• 2026 launch of smart suture technology

---

1️⃣ 10. Corbion

Headquarters: Amsterdam, Netherlands
Key Offering: Block copolymer PGA for orthopedic fixation

Corbion develops resorbable plates and screws that combine high load capacity with complete biodegradation, supporting the trend toward fully resorbable implants.

Sustainability & Growth Initiatives:

• 2024 partnership with Medtronic
• 2025 launch of biodegradable fixation system
• 2026 expansion of European capacity

---

Medical Polyglycolic Acid (PGA) Market – View in Detailed Research Report

Medical Polyglycolic Acid (PGA) Market – View in Detailed Research Report

---

Outlook

Regulatory bodies in the United States and the European Union are tightening approval criteria for biodegradable medical devices, which is accelerating investment in PGA‑based solutions. The convergence of material science and digital health monitoring is also opening avenues for real‑time tracking of degradation in vivo, a development that could unlock new market segments.

---

Future Trends

• Adoption of PGA in 3D‑printed implants, enabling patient‑specific, resorbable constructs
• Advancement of copolymer blends to fine‑tune degradation timelines for drug delivery
• Expansion of PGA manufacturing into emerging economies, particularly Southeast Asia and Latin America
• Integration of digital tracking systems to monitor degradation and biocompatibility in real time
• Alignment with global regulatory frameworks to streamline approval of PGA‑based devices worldwide

---